ATHX - アサ―シス （Athersys Inc.） アサ―シスATHXのチャート
ATHXの企業情報
| symbol | ATHx |
|---|---|
| 会社名 | Athersys Inc （アサ―シス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アサーシス(Athersys Inc.)は主に再生医療の分野に焦点を当てた国際的なバイオ技術企業である。同社のマルチステム細胞療法（同種異系幹細胞製剤）は、リードプラットフォーム製品であり、後の段階の臨床開発段階にある。その臨床開発プログラムは、神経学的状態、心血管疾患、炎症性および免疫性障害、特定の肺疾患および多くの患者にとって注意の基準が限られているまたは不十分なその他の状態の治療に焦点を当てる。神経領域では、虚血性脳卒中による神経学的損傷の病歴を有する患者のマルチステム治療の可能性である第2相試験を評価した。同社は急性心筋梗塞（AMI）の病歴を有する患者に対するマルチステム細胞療法の投与のために米国で第II相臨床試験を開始した。 アサ―シスは、米国のバイオテクノロジ―企業。主に再生医療の分野に焦点を当て、炎症、免疫障害、神経学的疾患、心疾患、その他疾患の治療用の同種幹細胞製品を研究、開発、商品化する。主要なプラットフォ―ム製品は特許取得済の成人由来の量産可能な幹細胞製品MultiStem。本社はオハイオ州クリ―ブランド。 Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. |
| 本社所在地 | 3201 Carnegie Avenue Cleveland OH 44115-2634 USA |
| 代表者氏名 | Gil Van Bokkelen ギルヴァンボケレン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 216-431-9900 |
| 設立年月日 | 34973 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 66人 |
| url | www.athersys.com |
| nasdaq_url | https://www.nasdaq.com/symbol/athx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -23.71700 |
| 終値（lastsale） | 2.11 |
| 時価総額（marketcap） | 292411550.03 |
| 時価総額 | 時価総額（百万ドル） 292.41160 |
| 売上高 | 売上高（百万ドル） 22.02600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 239.05860 |
| 当期純利益 | 当期純利益（百万ドル） -23.56500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Athersys Inc. revenues increased from $2.1M to $20.5M. Net loss decreased 73% to $3.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other expense net increase from $84K to $295K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.11 to -$0.02. |
ATHXのテクニカル分析
ATHXのニュース
Athersys Inc. expands board of directors as it preps for MultiStem commercialization 2020/11/16 17:40:26 Crain's Cleveland
The clinical-stage regenerative medicine company in Cleveland said it has added Katherine Kalin, Baiju R. Shah and Jane Wasman as board members. It also said Dr. Lee Babiss, a director since 2010, has retired.
Athersys Announces Three Appointments to Board of Directors 2020/11/16 11:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.
Athersys shares third-quarter results, clinical trial progress 2020/11/13 20:10:44 Crain's Cleveland
The Cleveland biotechnology company has announced continued progress in clinical trials studying its MultiStem stem cell therapy.
Athersys Reports Third Quarter 2020 Results and Provides Corporate Update 2020/11/09 21:05:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications
Zacks Investment Research Lowers Athersys (NASDAQ:ATHX) to Sell 2020/10/24 07:22:50 Zolmax News
Zacks Investment Research cut shares of Athersys (NASDAQ:ATHX) from a hold rating to a sell rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused […]
Athersys Reports Second Quarter 2020 Results 2020/08/10 20:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
Athersys to Host Second Quarter Financial Results Call 2020/07/20 18:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference 2020/05/18 10:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys taking a leading role at the International Society of Cell ad Gene Therapy Conference and will discuss MultiStem and the ARDS clinical trial.
Athersys Reports First Quarter 2020 Results 2020/05/07 20:05:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Q1 Earnings reflects multiple achievements for the Company, including obtaining FDA authorization to initiate two additional clinical trials.
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS 2020/05/05 10:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy.
Athersys Reports Second Quarter 2020 Results 2020/08/10 20:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.
Athersys to Host Second Quarter Financial Results Call 2020/07/20 18:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.
Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference 2020/05/18 10:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys taking a leading role at the International Society of Cell ad Gene Therapy Conference and will discuss MultiStem and the ARDS clinical trial.
Athersys Reports First Quarter 2020 Results 2020/05/07 20:05:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Q1 Earnings reflects multiple achievements for the Company, including obtaining FDA authorization to initiate two additional clinical trials.
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS 2020/05/05 10:00:00 Business Wire
CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--The first patients have been enrolled in the Athersys COVID-19 induced ARDS clinical program using MultiStem cell therapy.